Archive

Measuring the outcomes of iSIMPATHY

Written by Christine Clark | 14 May 2021

Interview and article by Christine Clark. Dr Claire Scullin explains how the iSIMPATHY project has been designed to end up with sustainable scheme to manage polypharmacy that has… read more.

Diabetes study stumbles across undetected COVID-19 cases in children

Written by Gary Finnegan | 14 May 2021

Article written by Gary Finnegan. A study that screened children for early-stage type 1 diabetes has detected a rate of COVID-19 infection higher than the number of cases… read more.

European Commission approves Benlysta for adult patients with active lupus nephritis – GSK

Written by Charlie King | 13 May 2021

GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.

Partners of people with schizophrenia often have a psychiatric disorder

Written by Gary Finnegan | 13 May 2021

Article written by Gary Finnegan. It is well-established that the children of people with serious mental health issues can be affected by their parents’ illness. Now new research… read more.

How pharmacist prescribers will tackle polypharmacy

Written by Christine Clark | 13 May 2021

Interview and article by Christine Clark. Drs Claire Scullin and Joanne Brown describes how prescribing pharmacists will carry out in-depth medication reviews for hospital inpatients and make any… read more.

Pfizer and BioNTech receive Health Canada authorization of COVID-19 vaccine in adolescents

Written by Charlie King | 12 May 2021

Pfizer Canada ULC and BioNTech SE announced that Health Canada has expanded the Interim Order authorization for their COVID-19 vaccine to include individuals 12 to 15 years of… read more.

The problems with polypharmacy

Written by Christine Clark | 12 May 2021

Interview and article by Christine Clark Polypharmacy, or the concomitant use of multiple medicines, is estimated to cost $18 billion and account for 8.6 million hospital admissions annually… read more.

EU gives green light for new medicines

Written by Gary Finnegan | 12 May 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) key committee, known as the CHMP, has recommended approval of eight medicines at its latest meeting. While the… read more.

New analysis of Uplizna for neuromyelitis optica spectrum disorder is published in Neurology Neuroimmunology & Neuroinflammation – Horizon Therapeutics

Written by Charlie King | 11 May 2021

Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.

EMA and ECDC join forces to monitor COVID-19 vaccines

Written by Gary Finnegan | 11 May 2021

Article written by Gary Finnegan. The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) has unveiled a new initiative aimed at strengthening post-marketing monitoring… read more.

Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated Joint Committee on Vaccination and Immunisation (UK) statement

Written by Charlie King | 10 May 2021

Department of Health & Social Care (UK) Statement made on 7 May 2021:There have been reports of extremely rare adverse events of concurrent thrombosis (blood clots) and thrombocytopenia… read more.

EU boost for vaccine production and paediatric use

Written by Gary Finnegan | 10 May 2021

Article written by Gary Finnegan. A flurry of activity at the European Medicines Agency (EMA) has provided a much-needed shot in the arm for European immunisation programmes. The… read more.

« Previous 1 … 40 41 42 43 44 … 63 Next »

Archive

Subscribe for our mailing list

Follow Us